Leerink Partnrs Issues Optimistic Forecast for AMLX Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Research analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for Amylyx Pharmaceuticals in a report released on Tuesday, May 6th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($0.47) per share for the quarter, up from their previous forecast of ($0.52). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals’ Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.85) EPS, FY2027 earnings at ($1.80) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.40) EPS.

Several other analysts have also recently weighed in on AMLX. Leerink Partners raised shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $4.00 to $10.00 in a research note on Wednesday. Mizuho raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their price target for the company from $3.00 to $7.00 in a report on Monday, April 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.00.

Amylyx Pharmaceuticals Stock Performance

AMLX opened at $4.65 on Friday. The firm has a market cap of $413.80 million, a price-to-earnings ratio of -1.22 and a beta of -0.60. The firm’s 50-day simple moving average is $4.01 and its 200-day simple moving average is $4.23. Amylyx Pharmaceuticals has a twelve month low of $1.58 and a twelve month high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.03.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in Amylyx Pharmaceuticals by 18.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,188 shares of the company’s stock valued at $61,000 after buying an additional 2,653 shares during the period. Blue Trust Inc. boosted its stake in Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after acquiring an additional 4,883 shares during the last quarter. XTX Topco Ltd grew its holdings in Amylyx Pharmaceuticals by 12.0% during the fourth quarter. XTX Topco Ltd now owns 53,376 shares of the company’s stock valued at $202,000 after purchasing an additional 5,704 shares during the period. Valeo Financial Advisors LLC bought a new stake in Amylyx Pharmaceuticals in the first quarter valued at approximately $35,000. Finally, Northern Trust Corp raised its holdings in Amylyx Pharmaceuticals by 11.8% in the fourth quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock worth $403,000 after purchasing an additional 11,214 shares during the period. Institutional investors and hedge funds own 95.84% of the company’s stock.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 21,490 shares of the business’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $74,570.30. Following the completion of the sale, the chief executive officer now directly owns 3,355,280 shares of the company’s stock, valued at approximately $11,642,821.60. The trade was a 0.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Camille L. Bedrosian sold 12,425 shares of the firm’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $43,114.75. Following the completion of the transaction, the insider now directly owns 194,375 shares in the company, valued at $674,481.25. This trade represents a 6.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,980 shares of company stock worth $168,627 over the last 90 days. 11.70% of the stock is owned by insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.